Novo Nordisk's Multi-Pronged Push: Cheaper Doses, Share Buybacks, and a Cloud Alliance
Published on 08/19/2026 at 14:12 | Redaktion boerse-global.de
The Danish pharma giant is attacking its problems from several angles at once. While investors fixate on a share price that has shed roughly a tenth of its value since January, management is quietly engineering a response that spans clinical trials, capital returns, and courtroom defenses.
The most consequential move came on August 12, when Novo Nordisk kicked off a late-stage study hunting for the lowest effective dose of its oral Wegovy pill. The trial will enroll 450 adults with a body-mass index of at least 27 plus a comorbidity, or 30 or higher without one, testing two lower—and as yet unspecified—doses against placebo. The primary endpoint is weight loss at 60 weeks, with results expected by 2028.
The economics behind the trial are straightforward. More than two-thirds of US patients are already taking the lowest available tablet dose, and for those paying out of pocket, a smaller amount of active ingredient translates to roughly half the cost. Since the pill's US launch at the start of the year, Novo Nordisk has logged over five million prescriptions.
Oral Wegovy generated second-quarter sales of 3.22 billion Danish kroner, which the company says comfortably outstrips the 98 million US dollars Eli Lilly's competing pill Foundayo brought in over the same stretch. The gap reflects a broader clinical edge: in trials, Novo Nordisk's tablet delivered 16.6 percent weight loss after 72 weeks, versus 11.2 percent for Lilly's offering.
A Shareholder-Friendly Fortnight
While the clinical work proceeds, the company has been returning capital to shareholders. Between August 10 and 14, Novo Nordisk repurchased one million B-shares for 302.6 million Danish kroner, lifting its treasury holdings to 42,924,876 B-shares—equivalent to one percent of share capital. The buyback is part of an ongoing program and signals management's conviction in the company's valuation even as the stock struggles.
Investors collecting the dividend on August 25—for those on the register as of August 17—will receive 0.5786 US dollars per share.
The capital discipline comes alongside a technology bet. On August 17, Novo Nordisk unveiled a partnership with Amazon Web Services, naming the cloud giant its preferred provider and establishing a co-innovation center in London focused on agentic AI and cloud technologies for drug discovery. For shareholders, it's a signal that the company intends to accelerate its research pipeline despite softer recent growth.
Legal Wins and Legal Fights
The patent front has been busy on multiple fronts. A US federal court in Texas dismissed an antitrust suit brought by compounding pharmacy Strive Specialties against both Novo Nordisk and Eli Lilly, ruling that the plaintiff failed to prove compounded and branded GLP-1 products were interchangeable in the manner alleged. In The Hague, the company secured a preliminary injunction against Ceban Ziekenhuisfarmacie over a counterfeit semaglutide nasal spray that infringed a supplementary protection certificate.
But Novo Nordisk is also playing offense. The company is suing telehealth provider Hims & Hers for patent infringement—a case one Danish patent attorney describes as potentially pivotal for the entire market. And in July, it filed a lawsuit against Eli Lilly over allegedly misleading advertising, claiming Lilly compares Zepbound to an older, lower-dose version of Wegovy. CEO Mike Doustdar has called the Lilly ads technically accurate but incomplete.
While Novo Nordisk defends its intellectual property in court, many UK employers face their own legal exposure in a different arena: workplace safety. A single missing risk assessment can leave a business vulnerable to enforcement action and fines. The free Risk Assessment Toolkit provides 41 ready-to-use templates and checklists to help you document hazards properly and stay compliant. Download the free Risk Assessment Toolkit
Pricing Pressures Mount
The search for cheaper doses unfolds against intensifying price competition. Novo Nordisk has pledged to cut its list price in half by 2027, while Lilly already offers Zepbound at 299 US dollars per month through its LillyDirect channel. In response, Novo Nordisk has rolled out subscription models for Wegovy through partners including Ro, WeightWatchers, LifeMD, Sesame, and Hims & Hers—a program that could save patients up to 1,200 US dollars annually on the injection and 600 US dollars on the tablet.
The Market Remains Skeptical
The stock closed Tuesday at 39.52 euros, up 1.7 percent on the day, but the monthly picture is less flattering: a 9.1 percent decline over the past four weeks and a 10 percent drop year-to-date. The shares sit 28 percent below their 52-week high of 54.86 euros, reached in late January. The current price of 39.37 euros is 5.2 percent below the 50-day average of 41.50 euros, reflecting the cautious mood that has prevailed in recent weeks. Technical indicators offer little clarity—the RSI of 42.2 suggests neither overbought nor oversold conditions, while annualized volatility of 40 percent points to persistently nervous trading.
Analysts are holding their fire. Deutsche Bank Research maintained its "Hold" rating with a price target of 290 Danish kroner, with analyst Emmanuel Papadakis seeing no immediate reason for an upgrade. Meanwhile, consensus forecasts for the obesity drug Cagrisema's sales through 2030 have been cut by more than 100 billion Danish kroner, according to the Danish newspaper Börsen—though Doustdar remains publicly confident in the product.
The coming months will test whether these efforts—the dose-optimization trial, the buybacks, the AI partnership, and the legal victories—can restore investor confidence. The capital markets day on September 21, where management will lay out strategy and financial targets, and the nine-month results due November 4, should provide the first clear read on whether the multi-pronged approach is working.
